Supriya Lifescience Secures WHO GMP Certification for Ambernath Facility with ₹500 Crore Revenue Potential

Supriya Lifescience has received the World Health Organization’s Good Manufacturing Practice (WHO GMP) certification for its manufacturing facility located in Ambernath, Maharashtra. This approval allows the company to commence commercial production of pharmaceutical formulations at the site, with an estimated revenue potential of ₹500 crore.

The certification confirms that the Ambernath facility meets international standards for quality and safety in pharmaceutical manufacturing. The WHO GMP approval is a significant milestone for Supriya Lifescience, as it enables the company to expand its operations and cater to global markets requiring adherence to stringent regulatory norms. The projected revenue from this development underscores the strategic importance of this certification for the company’s growth trajectory.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: October 3, 2025

Related posts:

Plozasiran Lowers Cholesterol and Triglyceride Levels in Mixed Hyperlipidemia Patients, Study Finds EMA Issues Recommendations to Address Supply Chain Vulnerabilities in Radiopharmaceuticals FDA Rejects Replimune’s Skin Cancer Therapy Following Input from Top Oncology Drug Regulator Penn State Researchers Develop Device to Detect Biomarkers in Minimal Sweat Levels

Author

Mark Chiang